Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy

Volumn 42, Issue 6, 1998, Pages 793-802

  Corbella, Xavier ^a   Ariza, Javier ^a   Ardanuy, Carmen ^a   Vuelta, Maria ^a   Tubau, Fe ^a   Sora, Mercedes ^a   Pujol, Miquel ^a   Gudiol, Francesc ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; IMIPENEM; SULBACTAM;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; BRONCHITIS; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DRUG POTENTIATION; FEMALE; HOSPITAL INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PNEUMONIA; URINARY TRACT INFECTION; WOUND INFECTION;

ACINETOBACTER; ACINETOBACTER INFECTIONS; AGED; AMPICILLIN; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; SULBACTAM; TREATMENT OUTCOME;

EID: 0032416554     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/42.6.793     Document Type: Article

References (58)

1. Bergogne-Berezin, E. & Joly-Guillou, M. L. (1991). Hospital infection with Acinetobacter spp.: an increasing problem. Journal of Hospital Infection 18, Suppl. A, 250-5.
2. Bergogne-Berezin, E. & Joly-Guillou, M. L. (1991). Antibiotic resistance mechanisms in Acinetobacter. In The Biology of Acinetobacter (Towner, K. J., Bergogne-Berezin, E. & Fewson, C. A., Eds), pp. 83-115. Plenum, New York.
3. Bergogne-Berezin, E. & Towner, K. J. (1996). Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clinical Microbiology Reviews 9, 148-65.
4. Cisneros, J. M., Reyes, M. J., Pachon, J., Becerril, B., Caballero, F. J., Garcia-Garmendia, J. L. et al. (1996). Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clinical Infectious Diseases 22, 1026-32.
5. Gehrlein, M., Leying, H., Cullmann, W., Wendt, S. & Opferkuch, W. (1991). Imipenem resistance in Acinetobacter baumannii is due to altered penicillin-binding proteins. Chemotherapy 37, 405-12.
6. Go, E. S., Urban, C., Burns, J., Kreiswirth, B., Eisner, W., Mariano, N. et al. (1994). Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 344, 1329-32.
7. Lyytikainen, O., Koljalg, S., Harma, M. & Vuopio-Varkila, J. (1995). Outbreak caused by two multi-resistant Acinetobacter baumannii clones in a burns unit: emergence of resistance to imipenem. Journal of Hospital Infections 31, 41-54.
8. Tankovic, J., Legrand, P., De Gatines, G., Chemineau, V., Brun-Buisson, C. & Duval, J. (1994). Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods. Journal of Clinical Microbiology 32, 2677-81.
9. Wood, C. A. & Reboli, A. C. (1993). Infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. Journal of Infectious Diseases 168, 1602-3.
10. English, A. R., Retsema, J. A., Girard, A. E., Lynch, J. E. & Barth, W. E. (1978). CP-45,899, a β-lactamase inhibitor that extends the antibacterial spectrum of β-lactams: initial bacteriological characterization. Antimicrobial Agents and Chemotherapy 14, 414-9.
11. Kitzis, M. D., Goldstein, F. W., Labia, R. & Acar, J. F. (1983). Activité du sulbactam et de l'acide clavulanique, seuls et associés, sur Acinetobacter calcoaceticus. Annales de Microbiologie 134A, 163-8.
12. Labia, R., Morand, A., Lelievre, V., Mattioni, D. & Kazmierczak, A. (1986). Sulbactam: biochemical factors involved in its synergy with ampicillin. Reviews of Infectious Diseases 8, Suppl. 5, 496-502.
13. Obana, Y. & Nishino, T. (1990). In-vitro and in-vivo activities of sulbactam and YTR830H against Acinetobacter calcoaceticus. Journal of Antimicrobial Chemotherapy 26, 677-82.
14. Jones, R. N. (1988). In vitro evaluations of aminopenicillin/β-lactamase inhibitor combinations. Drugs 35, Suppl. 7, 17-26.
15. Retsema, J. A., English, A. R., Girard, A., Lynch, J. E., Anderson, M., Brennan, L. et al. (1986). Sulbactam/ampicillin: in vitro spectrum, potency, and activity in models of acute infection. Reviews of Infectious Diseases 8, Suppl. 5, 528-34.
16. Shi, Z. Y., Liu, P. Y., Lau, Y., Lin, Y., Hu, B. S. & Shir, J. M. (1996). Antimicrobial susceptibility of clinical isolates of Acinetobacter baumannii. Diagnostic Microbiology and Infectious Disease 24, 81-5.
17. Urban, C., Go, E., Mariano, N. et al. (1995). Interactions of sulbactam, clavulanic acid and tazobactam with penicillin binding proteins of imipenem resistant and susceptible Acinetobacter baumannii. FEMS Microbiology Letters 125, 193-6.
18. Jiménez-Mejías, M. E., Pachón, J., Becerril, B., Palomino-Nicás, J., Rodríguez-Cobacho, A. & Revuelta, M. (1997). Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Clinical Infectious Diseases 24, 932-5.
19. Levin, A. S., Manrique, A. E. I., Medeiros, E. A. S., Cursino, R., Santos, C. R., Sielfeld, M. E. et al. (1997). Treatment of severe infection by multiresistant Acinetobacter baumannii with ampicillin/sulbactam - preliminary report. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997. Abstract LM-19, p. 367. American Society for Microbiology, Washington, DC.
20. Telenti, M., Moreno, A., Ruiz, J. & Fernández-Bernaldo, J. (1995). Eficacia de sulbactam-ampicilina en la infección urinaria por Acinetobacter calcoaceticus var. anitratus. Medicina Clínica 105, 38-9.
21. Urban, C., Go, E., Mariano, N., Berger, B. J., Avraham, I., Rubin, D. et al. (1993). Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. Journal of Infectious Diseases 167, 448-51.
22. Corbella, X., Pujol, M., Ayats, J., Sendra, M., Ardanuy, C., Domínguez, M. A. et al. (1996). Relevance of digestive tract colonization in the epidemiology of nososcomial infections due to multiresistant Acinetobacter baumannii. Clinical Infectious Diseases 23, 329-4.
23. Ayats, J., Corbella, X., Ardanuy, C., Dominguez, M. A., Ricart, A., Ariza, J. et al. (1997). Epidemiological significance of cutaneous, pharyngeal, and digestive tract colonization by multi-resistant Acinetobacter baumannii in ICU patients. Journal of Hospital Infection 37, 287-95.
24. Garner, J. S., Jarvis, W. R., Emori, T. G., Horan, T. C. & Hughes, J. M. (1988). CDC definitions for nosocomial infections, 1988. American Journal of Infection Control 16, 128-40.
25. National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fourth Edition: Document M7-A3. NCCLS, Villanova, PA.
26. National Committee for Clinical Laboratory Standards. (1992). Methods for Determining Bactericidal Activity of Antimicrobial Agents - Tentative Guideline: Document M26-T. NCCLS, Villanova, PA.
27. Bergogne, E., Zechovsky, N., Piechaud, M., Vieu, J. F. & Bordini, A. (1971). Sensibilité aux antibiotiques de 240 souches de Moraxella oxydase-négative (Acinetobacter) isolées d'infections hospitalières. Evolution sur 3 ans. Pathologie Biologie 19, 981-90.
28. Morohoshi, T. & Saito, T. (1977). Beta-lactamase and beta-lactam antibiotic resistance in Acinetobacter anitratus (syn: A. calcoaceticus). Journal of Antibiotics 30, 969-73.
29. Bergogne-Berezin, E., Joly-Guillou, M. L. & Vieu, J. F. (1987). Epidemiology of nosocomial infections due to Acinetobacter calcoaceticus. Journal of Hospital Infection 10, 105-13.
30. Joly-Guillou, M. L., Vallee, E., Bergogne-Berezin, E. & Philippon, A. (1988). Distribution of β-lactamases and phenotype analysis in clinical strains of Acinetobacter calcoaceticus. Journal of Antimicrobial Chemotherapy 22, 597-604.
31. Clark, R. B. (1996). Imipenem resistance among Acinetobacter baumannii: association with reduced expression of a 33-36 KDa outer membrane protein. Journal of Antimicrobial Chemotherapy 38, 245-51.
32. Scaife, W., Young, H. K., Paton, R. H. & Amyes, S. G. (1995). Transferable imipenem-resistance in Acinetobacter species from a clinical source. Journal of Antimicrobial Chemotherapy 36, 585-6.
33. Jacoby, G. A. & Sutton, L. (1989). Pseudomonas cepacia susceptibility to sulbactam. Antimicrobial Agents and Chemotherapy 33, 583-4.
34. Villar, H. E., Laurino, C. & Hoffman, M. (1996). Actividad bactericida de sulbactam frente a bacterias pertenecientes al complejo Acinetobacter calcoaceticus-Acinetobacter baumannii. Enfermedades Infecciosas y Microbiología Clínica 14, 524-7.
35. Auckenthaler, R., Von Graevenitz, A., Michea-Hamzehpour, M., Wüst, J. & Zollinger-Iten, J. (1986). Effect of sulbactam-ampicillin on ampicillin-resistant bacteria in two Swiss hospitals. Current Therapeutic Research 40, 1078-83.
36. Frank, U. & Daschner, F. D. (1989). In vitro activity of sulbactam plus ampicillin against hospital isolates of coagulase-negative staphylococci and Acinetobacter species. Infection 17, 272-4.
37. Klastersky, J. & Van der Auwera, P. (1989). In vitro activity of sulbactam in combination with various β-lactam antibiotics. Diagnostic Microbiology and Infectious Disease 12, Suppl. 4, 165S-9S.
38. Kuah, B. G., Kumarasinghe, G., Doran, J. & Chang, H. R. (1994). Antimicrobial susceptibilities of clinical isolates of Acinetobacter baumannii from Singapore. Antimicrobial Agents and Chemotherapy 38, 2502-3.
39. Bauernfeind, A., Kljucar, S. & Jungwirth, R. (1997). Overview of antibiotic resistance problems in Acinetobacter spp. Journal of Medical Microbiology 46, 726-8.
40. Aubert, G., Guichard, D. & Vedel, G. (1996). In-vitro activity of cephalosporins alone and combined with sulbactam against various strains of Acinetobacter baumannii with different antibiotic resistance profiles. Journal of Antimicrobial Chemotherapy 37, 155-60.
41. Casellas, J. M. & Dana, R. (1996). Es realmente el sulbactam una solución para el tratamiento de infecciones producidas por cepas multirresistentes de Acinetobacter spp.? Enfermedades Infecciosas y Microbiología Clínica 15, 335-6.
42. Kazmierczak, A., Pechinot, A., Siebor, E., Cordin, X. & Labia, R. (1989). Sulbactam: secondary mechanisms of action. Diagnostic Microbiology and Infectious Disease 12, Suppl. 4, 139S-46S.
43. Foulds, G. (1986). Phamacokinetics of sulbactam/ampicillin in humans: a review. Reviews of Infectious Diseases 8, Suppl. 5, S503-11.
44. Foulds, G., Stankewich, J. P., Marshall, D. C., O'Brien, M. M., Hayes, S. L., Weidler, D. J. et al. (1983). Pharmacokinetics of sulbactam in humans. Antimicrobial Agents and Chemotherapy 23, 692-9.
45. Meyers, B. R., Wilkinson, P., Mendelson, M. H., Walsh, S., Bournazos, C. & Hirschman, S. Z. (1991). Pharmacokinetics of ampicillin-sulbactam in healthy elderly and young volunteers. Antimicrobial Agents and Chemotherapy 35, 2098-101.
46. Barry, A. L., Jones, R. N. & Thornsberry, C. (1984). Interpretative standards and quality control limits for susceptibility tests with ampicillin-sulbactam combination disks. Journal of Clinical Microbiology 13, 134-9.
47. Jones, R. N. & Barry, A. L. (1987). Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination. Journal of Clinical Microbiology 25, 1920-5.
48. Jones, R. N. & Dudley, M. N. (1997). Microbiologic and pharmacodynamic principles applied to the antimicrobial susceptibility testing of ampicillin/sulbactam: analysis of the correlations between in vitro test results and clinical response. Diagnostic Microbiology and Infectious Disease 28, 5-18.
49. Wolff, M., Joly-Guillou, M. L. & Carbon, C. (1996). In-vivo efficacy of β-lactamase inhibitors alone and in combination against Acinetobacter baumannii in a mouse pneumonia model. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract B-61, p. 32. American Society for Microbiology, Washington, DC.
50. Wolff, M., Joly-Guillou, M. L., Farinotti, R. & Carbon, C. (1997). Efficacy of various regimens containing rifampin against multiresistant A. baumannii in a mouse pneumonia model. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997. Abstract B-S, p. 27. American Society for Microbiology, Washington, DC.
51. Mekonen, E. T., Noskin, G. A., Hacek, D. M. & Peterson, L. R. (1995). Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium. Microbial Drug Resistance 1, 249-53.
52. Rodriguez, W. J., Khan, W. N., Puig, J., Feris, J., Harmon, S., Gold, B. G. et al. (1986). Sulbactam/ampicillin vs. chloramphenicol/ampicillin for the treatment of meningitis in infants and children. Reviews of Infectious Diseases 8, Suppl. 5, S620-9.
53. Chow, A. W., Wong, J. & Bartlett, K. H. (1988). Synergistic interactions of ciprofloxacin and extended-spectrum β-lactams or aminoglycosides against Acinetobacter calcoaceticus ss. anitratus. Diagnostic Microbiology and Infectious Diseases 9, 213-7.
54. Joly-Guillou, M. L., Deere, D., Herrman, J. L., Bourdelier, E. & Bergogne-Berezin, E. (1995). Bactericidal in-vitro activity of β-lactams and β-lactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides. Journal of Antimicrobial Chemotherapy 36, 619-29.
55. Marques, M. B., Brookings, E. S., Moser, S. A., Sonke, P. B. & Waites, K. B. (1997). Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations. Antimicrobial Agents and Chemotherapy 41, 881-5.
56. Traub, W. H. & Spohr, M. (1989). Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, genospecies 3, and genospecies 6). Antimicrobial Agents and Chemotherapy 33, 1617-9.
57. Vila, J., Marcos, A., Marco, F., Abdalla, S., Vergara, Y., Reig, R. et al. (1993). In vitro antimicrobial production of β-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 37, 138-41.
58. McCabe, W. R. & Jackson, G. G. (1962). Gram-negative bacteremia. 1. Etiology and ecology. Archives of Internal Medicine 110, 847-55.